This company has been acquired
HEXO Resultados de beneficios anteriores
Pasado controles de criterios 0/6
HEXO's earnings have been declining at an average annual rate of -42.2%, while the Pharmaceuticals industry saw earnings growing at 31.8% annually. Revenues have been growing at an average rate of 39.8% per year.
Información clave
-42.2%
Tasa de crecimiento de los beneficios
-4.5%
Tasa de crecimiento del BPA
| Crecimiento de la industria Pharmaceuticals | 23.1% |
| Tasa de crecimiento de los ingresos | 39.8% |
| Rentabilidad financiera | -191.4% |
| Margen neto | -220.1% |
| Última actualización de beneficios | 30 Apr 2023 |
Actualizaciones de resultados anteriores recientes
Recent updates
Bearish: Analysts Just Cut Their HEXO Corp. (TSE:HEXO) Revenue and EPS estimates
Mar 21
The Consensus EPS Estimates For HEXO Corp. (TSE:HEXO) Just Fell Dramatically
Dec 15Does HEXO (TSE:HEXO) Have A Healthy Balance Sheet?
Aug 16Is HEXO (TSE:HEXO) Using Debt In A Risky Way?
Apr 16Are HEXO Corp. (TSE:HEXO) Investors Paying Above The Intrinsic Value?
Feb 23Desglose de ingresos y gastosBeta
Cómo gana y gasta dinero HEXO. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Apr 23 | 124 | -273 | 61 | 1 |
| 31 Jan 23 | 148 | -301 | 86 | 1 |
| 31 Oct 22 | 177 | -1,013 | 105 | 3 |
| 31 Jul 22 | 191 | -1,074 | 122 | 3 |
| 30 Apr 22 | 187 | -1,042 | 128 | 4 |
| 31 Jan 22 | 164 | -918 | 109 | 4 |
| 31 Oct 21 | 144 | -228 | 96 | 4 |
| 31 Jul 21 | 124 | -115 | 80 | 4 |
| 30 Apr 21 | 112 | -214 | 75 | 4 |
| 31 Jan 21 | 112 | -213 | 75 | 4 |
| 31 Oct 20 | 96 | -491 | 78 | 4 |
| 31 Jul 20 | 81 | -546 | 91 | 5 |
| 30 Apr 20 | 69 | -423 | 115 | 7 |
| 31 Jan 20 | 60 | -411 | 119 | 6 |
| 31 Oct 19 | 56 | -117 | 114 | 5 |
| 31 Jul 19 | 48 | -70 | 105 | 3 |
| 30 Apr 19 | 34 | -35 | 73 | 0 |
| 31 Jan 19 | 22 | -30 | 54 | 0 |
| 31 Oct 18 | 9 | -34 | 41 | 0 |
| 31 Jul 18 | 5 | -23 | 23 | 0 |
| 30 Apr 18 | 4 | -12 | 15 | 0 |
| 31 Jan 18 | 4 | -22 | 12 | 0 |
| 31 Oct 17 | 4 | -14 | 9 | 0 |
| 31 Jul 17 | 4 | -12 | 7 | 0 |
| 30 Apr 17 | 4 | -15 | 7 | 0 |
| 31 Jan 17 | 4 | -3 | 5 | 0 |
| 31 Oct 16 | 3 | -3 | 4 | 0 |
| 31 Jul 16 | 2 | -3 | 4 | 0 |
| 31 Jul 15 | 0 | -3 | 2 | 0 |
Ingresos de calidad: HEXO is currently unprofitable.
Margen de beneficios creciente: HEXO is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: HEXO is unprofitable, and losses have increased over the past 5 years at a rate of 42.2% per year.
Acelerando crecimiento: Unable to compare HEXO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: HEXO is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (58.7%).
Rentabilidad financiera
Alta ROE: HEXO has a negative Return on Equity (-191.4%), as it is currently unprofitable.